Table 3.
Subgroup analysis of concordant proportion between PSA and PSMA PET response assessments stratified to therapeutic agent and PSMA PET criteria.
| Variables | Subgroups | Studies (n) | Pooled Proportion | 95% CI | I 2 | p * |
|---|---|---|---|---|---|---|
| Therapeutic agents | 177Lu-PSMA | 5 | 0.78 | 0.71–0.85 | 0% | 0.69 |
| Chemotherapy | 3 | 0.74 | 0.61–0.86 | 0% | ||
| PET criteria | PSMA-TV | 5 | 0.72 | 0.62–0.82 | 36% | 0.33 |
| SUVmax | 4 | 0.68 | 0.56–0.79 | 0% | ||
| Summed SUVmean | 3 | 0.68 | 0.54–0.81 | 50% | ||
| TL-PSMA | 3 | 0.70 | 0.50–0.87 | 45% |
Subgroups containing ≥3 studies were shown; * p-values of test for subgroup differences; CI = confidence interval; NA = not applicable; PSMA-TV = PSMA tumor volume; SUV = standardized uptake value; TL-PSMA = total lesion PSMA.